Observational Study to Evaluate Effectiveness of Adding Empagliflozin to Uncontrolled Type 2 Diabetes Patients Who Were Uncontrolled On Metformin Rather Than Up Titrating the Metformin Dose
Abstract
Aim: The main objective of this prospective observational study to evaluate effectiveness of adding empagliflozin to uncontrolled type 2 diabetes patients who were uncontrolled on metformin rather than up titrating the metformin dose.
Material & Method: This was a prospective observational study conducted among 90 patients who had qualified as per the inclusion and exclusion criteria. After inclusion patients were divided into two groups one group 10 mg Empagliflozin OD were added with 1000 mg metformin OD (N=45) and in other group metformin were up titrated to 2000 mg OD (N=45) as this is considered as maximum tolerable dose of metformin.
Result: There was a significant weight reduction in Empa + Met group which was as high as 1 kg over 24 weeks’ time frame. Despite on adequate anti-hypertensive management in both the group further statistically significant reduction in both SBP and DBP were observed in Empa+Met group (10.2±3.5 mmHg and 7.2±2.6, respectively) which was not with Met group. There were a further statistically significant reduction in total cholesterol, triglyceride and LDL Cholesterol despite the group were on optimal dosage of lipid lowering therapy.
Conclusion: Empagliflozin 10 mg is a potent glucose lowering agent and should be added to patients who were initially uncontrolled with metformin monotherapy rather than up titrating metformin dose. Empagliflozin offer better pleotropic benefits when added as second line therapy to metformin.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.